A longstanding challenge in public health includes developing and disseminating innovative solutions for earlier detection, screening, and diagnosis of cancers. The advent of novel technologies for blood-based cancer detection have raised entirely new questions for how these tests should be evaluated and adopted. Diverse stakeholder collaboration is required to flesh out and resolve some of these questions and challenges. In this presentation, we will dig into the ongoing activities of two active consortia: the Multi-Cancer Early Detection (MCED) Consortium and BLOODPAC Screening and Early Detection Working Group, both of which have been set forth as collaborative multi-stakeholder venues for developing shared frameworks, aggregating supporting data, and accelerating evaluation.

Citation Format: Christina A. Clarke. The role of consortia building the paradigm of blood-based early cancer detection. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr IA024.